Eileen Epstein Carney
Eileen works closely with investors in securities cases and has over a decade of experience in the legal world. She received her law degree from American University in 2005.
Stock plummets over 20% after Advantage Loan program suspended
Shares of Sterling Bancorp, Inc. (NASDAQ: SBT) dropped over 22% on December 9th after the company disclosed that its subsidiary suspended its Advantage Loan program indefinitely in connection with an internal review of the Bank’s documentation and procedures. The Advantage Loan program is a major component of the Bank’s total loan originations, and the company announced that the suspension will reduce near-term loan originations, slow overall loan portfolio growth, and will likely result in less loan sales.
Our firm is investigating Sterling Bancorp on behalf of shareholders who lost money in the stock. You may be eligible for monetary recovery.
Lose Money in Sterling Bancorp?
Contact us about recovering your losses.
(Please provide number of shares, purchase date, and estimated losses.)
On December 9, 2019, Sterling Bancorp filed a Form 8-K with the Securities and Exchange Commission (SEC). The filing disclosed that Sterling Bancorp’s subsidiary, Sterling Bank and Trust, FSB, suspended its Advantage Loan program in connection with an ongoing internal review. The review includes an audit of documentation on past loans, as well as new loan regulation efforts. As stated in the Form 8-K,
Management believes it is prudent to temporarily halt the program as it continues to audit documentation on past loans and puts in place additional systems and controls to ensure the Bank’s policies and procedures are followed on loans originated under the program.
The filing further states that the program will not be resumed until “management is confident its stated policies and procedures are being followed.” However, the company was not able to predict how long the suspension may last.
While the effects of the suspension of the loan program cannot be fully known, the company anticipates, among other things, a reduction in loan sales. This decreased production may have adverse effects. According to the Form 8-K,
It is too early to assess the level of success that the Company will have in replacing the lost loan production volume from the Advantage Loan program’s temporary suspension. If the Company is unable to replace the lost production in a timely matter, or if a decision is made to alter the program, the Company’s results of operations could be materially and adversely affected.
On this news, Sterling Bancorp share price plummeted nearly 22% during intraday trading on December 9th. Our firm will continue to investigate.
Our securities lawyers have recovered over a billion dollars on behalf of our clients against behemoths, such as Chase Bank, Mastercard, and Anthem Blue Cross Blue Shield. Read more about our results.
You “shouldn’t presume that powerful banks and other powerful interests can just get away with doing bad things. Good, qualified counsel that are committed to a cause can usually figure out how to prosecute such cases effectively and prevail.”
–Eric Gibbs, award-winning securities attorney
Federal judge in our AT&T class action:
“I’ve always found them to be extraordinary counsel in terms of their preparation and their professionalism.”
Federal judge in our Chase lawsuit (resulting in $100 million settlement):
They “fought tooth and nail, down to the wire” to achieve “the best settlement that they could under the circumstances.”
Read more about what judges say about us.
Eileen works closely with investors in securities cases and has over a decade of experience in the legal world. She received her law degree from American University in 2005.
David’s advocacy has generated major recoveries for consumers impacted by financial fraud. He was named to the Top 40 Under 40 by Daily Journal and a “Rising Star in Class Actions” by Law360.
Amanda is spearheading a securities lawsuit against NantHealth concerning fraudulent statements to investors about the success of its key product.